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ABSTRACT
Cyclin-dependent kinase inhibitor p27Kip1 functions at the nuclear
level by binding to cyclin E/cyclin-dependent kinase-2. It was shown that
Akt or protein kinase B (Akt/PKB)-dependent phosphorylation of
p27Kip1 led to the cytoplasmic mislocalization of p27Kip1, suggesting the
potential abrogation of its activity. Here, we evaluated the localization of
p27Kip1 protein in leukemic blasts in relation to Akt/PKB phosphoryla-
tion and clinical outcomes in acute myelogenous leukemia (AML). West-
ern blot analysis of the nuclear and cytoplasmic fractions revealed a
heterogenous localization pattern of p27Kip1 in AML. Cytoplasmic mis-
localization of p27Kip1 was significantly associated with the constitutive
serine473 Akt/PKB phosphorylation in AML cells (P < 0.05). Transfection
of U937 cells with an expression construct encoding the constitutively
active form of Akt/PKB resulted in a remarkable increase in the levels of
cytoplasmic p27Kip1. Whereas the transfection of U937 cells with a
construct encoding dominant-negative Akt/PKB resulted in a recovery of
nuclear localization of p27Kip1. Both the disease-free survival and overall
survival are significantly shorter in AML cases with high cytoplasmic to
nuclear ratio of p27Kip1 localization compared with the cases with low
cytoplasmic to nuclear ratio (P  0.0353, P  0.0023, respectively).
Multivariate analysis indicated that the cytoplasmic to nuclear ratio of
p27Kip1 localization was an independent prognostic variable for both
disease-free survival and overall survival (P  0.043, P  0.008, respec-
tively). These findings additionally extend our understanding of the role of
p27Kip1 in AML, and buttress the case of p27Kip1 mislocalization as a
prognostic indicator and Akt/PKB/p27Kip1 pathway as a ready target for
antileukemia therapy.
INTRODUCTION
The cyclin-dependent kinase (CDK) inhibitor p27Kip1 is an im-
portant regulator of G1 progression and negatively regulates cell
proliferation. It is expressed highly in G0, where it binds tightly and
inhibits cyclin E/CDK-2 (1–4). The p27Kip1 protein levels are reg-
ulated predominantly by ubiquitin/proteasome-mediated proteolysis
(4, 5) in a process that requires its association with cyclin/CDK
complexes (6, 7) and phosphorylation of the threonine (Thr)187 of the
p27Kip1 protein (6, 8, 9). The expression of S-phase kinase-associ-
ated protein 2, a member of the F-box family of the specific substrate-
recognition subunit of Skp1/Cull/F-box (SCF) ubiquitin-protein ligase
complexes (10) is required for the ubiquitination and subsequent
degradation of p27Kip1 (11–15).
Although p27Kip1 is rarely mutated in human cancers, there are
considerable evidences that the inactivation of p27Kip1 is a funda-
mental step for the development of malignancies (16–19). The re-
duced expression of p27Kip1, because of increased protein degrada-
tion, correlates with the poor prognosis of patients with various types
of cancer (16, 17, 19–23). Paradoxically, some tumors may contain
elevated levels of p27Kip1 protein (17, 20, 23), suggesting that they
have developed other mechanisms to circumvent p27Kip1 growth
inhibition. High levels of p27Kip1 might inhibit the efficacy of
chemotherapeutic agents, which rely on the interfering with the cell
proliferation to trigger a cytotoxic response (18, 24). This opposing
effect of p27Kip1 as a prognostic relevance prompts additional efforts
to understand the mechanisms involved in the modulation of the
p27Kip1 activity and its consequences on the therapeutic outcomes in
specific tumors.
In human tumors, p27Kip1 protein itself, or its activity, appears to
be lost by increased cytoplasmic mislocalization or sequestration as
well as increased degradation (25). In tumors with abundant p27Kip1
expression, the protein is often mislocalized to the cytoplasm (26–28).
Because the growth-restraining activity of p27Kip1 depends on its
nuclear localization, the cytoplasmic mislocalization can effectively
inactivate the p27Kip1 inhibitory activity (26, 29–32). Cytoplasmic
p27Kip1 appears to directly correlate with a poor prognosis and
advanced tumor grade of esophagus and breast carcinoma (28, 33, 34).
These findings suggest that the elucidation of the mechanisms impli-
cated in the regulation of p27Kip1 mislocalization can provide the
insight into the aberrant p27Kip1 regulatory pathway and its role in
tumor cells.
Akt or protein kinase B (Akt/PKB) is a central component of the
phosphatidylinositol 3-kinase pathway (35–37), a pathway replete
with oncogenetically relevant molecules (38). Akt/PKB can down-
regulate the p27Kip1 by increasing its proteolysis (39) or repressing
its expression through Akt/PKB-mediated phosphorylation of the
forkhead transcription factor (40). Recently, a novel mechanism of
Akt/PKB-mediated p27Kip1 regulation was demonstrated (34, 41).
The p27Kip1 is phosphorylated at Thr157 by Akt/PKB both in vitro
and in vivo (33, 41). This Akt/PKB-dependent phosphorylation results
in an impairing of nuclear import of p27Kip1 protein, leading to its
cytoplasmic mislocalization and abrogation of its cyclin E/CDK2
inhibitory activity (33, 41). The Akt/PKB phosphorylation has been
shown to correlate statistically with the cytosolic mislocalization of
p27Kip1 in tumor cells (33, 41). These data indicate that Akt/PKB
activation may contribute to the tumor-cell proliferation via phospho-
rylation and cytoplasmic retention of p27Kip1, thus, relieving CDK2
from the p27Kip1-induced inhibition.
We demonstrated previously that the constitutive phosphorylation
of Akt/PKB was observed in a substantial proportion of acute my-
elogenous leukemia (AML) and associated with a poor prognosis (42).
However, the cytoplasmic mislocalization of p27Kip1 protein in re-
lation to Akt/PKB phosphorylation and clinical outcomes has not been
evaluated in AML. In this study, the constitutive phosphorylation of
Akt/PKB was correlated highly with the cytoplasmic mislocalization
of p27Kip1 protein in AML. The induced overexpression of Akt/PKB
activity in leukemia cells resulted in a markedly increased localization
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of p27Kip1 to the cytoplasm. The pronounced cytoplasmic mislocal-
ization of p27Kip1 was significantly associated with the reduced
survival in AML and remained an independent prognostic factor in a
multivariate analysis. These findings additionally extend our under-
standing of the role of p27Kip1 in AML and support the case of
p27Kip1 mislocalization as a prognostic indicator and the Akt/PKB/
p27Kip1 pathway as a ready target for antileukemia therapy.
MATERIALS AND METHODS
Patients and Treatment. A total of 99 consecutive adults with de novo
AML who had not received treatment were included in the study. According
to the French-American-British classification, 4 patients had M0, 20 M1, 33
M2, 19 M4, 21 M5, and 2 M6 subtype. Patients with AML (M3) were excluded
from the study. Eighty patients received induction chemotherapy, comprising
of cytarabine (100 mg/m2/d by continuous infusion for 7 days) and idarubicin
(12 mg/m2/d IV bolus for 3 days). Complete remission was defined as the
normalization of blood counts and bone marrow morphology and the disap-
pearance of all signs of leukemia, for at least 4 weeks or longer, in accordance
with the recommendations of the National Cancer Institute-sponsored Work-
shop (43). All of the patients achieving complete remission then received the
same two courses of consolidation chemotherapy consisting of cytarabine
(1g/m2/d IV infusion for 2 h every 12 h for 4 days), mitoxantrone (12 mg/m2/d
for 3 days), and VP-16 (100 mg/m2/d for 2 days) as described previously (44).
Isolation of Leukemic Cells. In conjunction with the institutional review
board-approved treatment protocol, bone marrow aspirates were prepared
prospectively from the patients before the initiation of chemotherapy. Marrows
were sedimented on a Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Sweden)
density gradient. After washing the mononuclear cells collected from the upper
interface, T-cell depletion was performed using a high-gradient magnetic cell
separation system/anti-CD3 monoclonal antibody (Miltenyi Biotech, Auburn,
CA) according to the manufacturer’s instructions. A morphological evaluation
indicated that 95% of the isolated cells were leukemic blasts.
Cell Line. The U937 human leukemia cell line was purchased from the
American Type Culture Collection (Manassas, VA). The cells were grown in
RPMI 1640 (Life Technologies, Inc., Rockville, MD) supplemented with 10%
(v/v) heat-inactivated fetal bovine serum (HyClone Laboratories, Logan, UT),
1% penicillin/streptomycin, sodium pyruvate, and 2 mM L-glutamine (Life
Technologies, Inc.).
Antibodies and Reagents. The rabbit polyclonal antibodies against total
Akt/PKB and phospho-serine (Ser)473 Akt/PKB were purchased from Cell
Signaling Technology (Beverly, MA). The mouse monoclonal antibody
against p27Kip1 was obtained from Zymed (San Francisco, CA). The rabbit
polyclonal antibody against p27Kip1, HRP-conjugated goat-antimouse IgG
and HRP-conjugated goat-antirabbit IgG were obtained from Transduction
Laboratories (Lexington, KY). The antihuman -tubulin monoclonal antibody
was from Cedarlane (Ontario, Canada). The protein A-agarose bead was from
Upstate Biotechnologies (Lake Placid, NY). All of the other culture reagents
were purchased from Life Technologies, Inc. unless indicated otherwise.
Cytogenetic Analysis. Cytogenetic G-banding analysis was performed on
pretreated bone marrow cells. The definition of the cytogenetic clone and
descriptions of karyotypes followed the International System for Human
Cytogenetic Nomenclature. Patients were divided into three prognostic groups
based on their karyotype: (a) prognostic groups were favorable [t(8;21),
inv(16)]; (b) intermediate (normal cytogenetics); and (c) unfavorable (all other
abnormalities).
Cell Cycle Analysis. Leukemic cells were pelleted, fixed in 70% ethanol
on ice for 1 h, and resuspended in 1 ml of cell cycle buffer (0.38 mM sodium
citrate, 0.5 mg/ml RNase A, and 0.01 mg/ml propidium iodide) at a concen-
tration of 106 cells/ml. Cell cycle analysis was carried out using a FACSCali-
bur flow cytometer equipped with CellQuest software (Becton Dickinson, San
Jose, CA).
Transient Transfection. Cells were plated in 12-well plates containing
RPMI 1640 supplemented with 10% (v/v) fetal bovine serum and 1% penicil-
lin/streptomycin at a density of 2 106 cells/well. The next day, a transfection
mixture was prepared by mixing 5 g of DNA (expression vectors) with 100
l of human Nucleofector solution (Amaxa Biosystems, Gaithersburg, MD),
Fig. 1. Western blot analyses of the p27Kip1 protein expression and localization in the representative acute myelogenous leukemia (AML) and normal bone marrrow (BM) samples.
A, the levels of p27Kip1 protein expression were variable according to the samples. The -tubulin was used as a control. B, the subcellular localization of the p27Kip1 protein was
analyzed by Western blotting of the nuclear and cytoplasmic fractions of the cell lysates as described in “Materials and Methods.”
Table 1 Patient characteristics and CRa rate according to the C:N ratio of p27Kip1
protein localization
C:N ratio of p27Kip1 expressionb
PLow (n  44) High (n  44)
Age (yr), median (range) 44 (15–75) 44 (20–75) NS
Sex (male/female) 24/18 25/32 NS
WBC (109/l), median (range) 16.5 (0.6–238.0) 24.7 (1.2–253.8) NS









CR rate 95% (38/40) 75% (30/40) NS
a CR, complete remission; C:N, cytoplasmic to nuclear; NS, not significant; WBC,
white blood cell; LDH, lactic dehydrogenase; FAB, French-American-British.
b C:N ratio of p27Kip1 localization; Low, 1.97; High, 1.97.
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which was then used to transfect 2 106 leukemia cells. Cells were transfected
with expression constructs encoding the constitutively active form of the
Akt/PKB (pcDNA3-myristoylated-Akt/PKB) or dominant negative (DN)-Akt/
PKB (pcDNA3-DN-Akt/PKB), which were kindly provided by Dr. Young-
Guen Kwon (Yonsei University, Seoul, Korea). The cell suspension was
immediately electroporated by a Nucleofector instrument (Amaxa Biosys-
tems), according to the manufacturer’s instructions. Immediately after electro-
poration, the cells were suspended in the complete medium and incubated in a
humidified 37°C/5% CO2 incubator. The cells were harvested 48 h after
transfection and used for the experiments. The experiments were repeated at
least three times.
Confocal Microscopy and Image Analysis. Confocal microscopy was
used to examine the localization of the p27Kip1 protein in AML cells. Cells
were fixed, permeabilized, and blocked with 2% BSA. Cells were incubated
with the primary antibody against p27Kip1 (1:100 dilution) for 1 h at 37°C and
then incubated with the corresponding FITC-conjugated secondary antibody
(1:200 dilution). After the cells had been spun down on a slide, the nuclei were
counterstained by 4,6-diamidino-2-phenylindole (Molecular Probes, Eugene,
OR) for 1 min. After washing, the slides were mounted in a drop of antifade
mounting medium (Vectashield; Vector Laboratories, Burlingame, CA). An-
tibody labeling was examined by a Bio-Rad 1024-UV confocal system at-
tached to a laser scanning confocal microscope (Leica Lasertechnick GmbH,
Heidelberg, Germany). Control experiments, with the omission of the primary
antibody, showed negative staining in all of the experiments. Simultaneous
FITC or 4,6-diamidino-2-phenylindole images were captured from the same
optical section. The captured images were then pseudocolored as follows: (a)
blue for 4,6-diamidino-2-phenylindole; and (b) green for FITC. Regions of
colocalization appear in cyan, reflecting the additive effect of superimposing
the green and blue pixels. Image analysis was performed using the standard
system operating software provided with the confocal microscope. All of the
illustrations were assembled and processed digitally (Adobe PhotoShop, ver-
sion 6.0; Adobe Systems Inc., San Diego, CA).
Preparation of Nuclear and Cytoplasmic Fractions. Cells were subfrac-
tionated, as described previously (45), with minor modifications. Briefly, cells
were pelleted by centrifugation (5 min, 12,000 rpm, 4°C) and incubated in a
hypotonic buffer [10 mM HEPES (pH 7.2), 10 mM KCl, 1.5 mM MgCl2, 0.1 mM
EGTA, 20 mM NaF, 100 M Na3VO4, and a 0.1% protease inhibitor cocktail;
Sigma Chemical, St. Louis, MO] for 30 min at 4°C, with rocking. Cells were
broken using a Dounce homogenizer (30 strokes), after which the nuclei were
pelleted by centrifugation (10 min, 3,500 rpm, 4°C). The nuclei-free superna-
tant was subjected to a second 10,000  g centrifugation for 45 min at 4°C to
separate the membranes from the cytosolic fractions. The nuclear pellets were
resuspended in nuclear lysis buffer [10 nM Tris-HCl (pH 7.5), 150 mM NaCl,
5 mM EDTA, and 1% Triton X-100], incubated for 1 min in a sonicating water
bath, then incubated for 30 min at 4°C, with rocking. Twenty g of total
cytosolic and nuclear proteins were analyzed by Western blotting.
Western Blotting. The cells were dissolved in 100 l of SDS-PAGE
sample buffer containing -mercaptoethanol to a final concentration of
3  106 cells. Lysates were sonicated for 15 s with a Vibra Cell Sonicator,
boiled for 10 min, and additionally analyzed by Western blotting. The protein
yields were quantified using the Bio-Rad Dc protein assay kit (Bio-Rad,
Hercules, CA) and equivalent amounts of protein applied to 15% acrylamide
gels. The proteins were separated by SDS-PAGE and transferred to nitrocel-
lulose membranes (Amersham Biosciences, Sunnyvale, CA). The membranes
were blocked with 3% BSA in Tris-buffered saline-Tween (TBST; 1  Tris-
buffered saline, 0.1% Tween 20) for 2 h. After washing twice in TBST, the
membranes were incubated with the primary antibodies for 2 h at room
temperature. The membranes were then washed four times in TBST and
incubated with the relevant horseradish peroxidase-conjugated secondary an-
tibodies (1:3000 dilution with 3% BSA in TBST) for 30 min. After washing
four times in TBST, the reactive proteins were visualized with an enhanced
chemiluminescence detection system (Amersham Biosciences). Densitometry
was performed by the Molecular Dynamics Imaging system and ImageQuant
3.3 software (Amersham Biosciences) to quantify relative amounts of protein
detected on the Western blots.
Statistical Analysis. The patients were divided into two groups (high and
low) in relation to the median value of the cytoplasmic to nuclear ratio (C:N)
of the p27Kip1 protein localization. Comparisons among the characteristics of
the groups were made using a chi-square test for the binary variables and a
Mann-Whitney test for the continuous variables. The disease-free survival
(DFS) and overall survival (OS) probabilities were calculated using the
Kaplan-Meier method. The log-rank statistic was used to test for the difference
in survival times between the groups. In addition to the p27Kip1 protein
localization, the WBC count, age, and cytogenetics were analyzed in the
Fig. 2. A, the levels of cytoplasmic to nuclear ratio (C:N) of the p27Kip1 protein localization in relation to the constitutive Akt or protein kinase B (Akt/PKB) phosphorylation in
acute myelogenous leukemia cells. The mean value of the C:N ratio of the p27Kip1 protein localization (E) was significantly higher in the pAkt/PKB-positive compared with the
pAkt/PKB-negative group (P  0.043; B) The constitutive Akt/PKB phosphorylation, according to the C:N ratio of p27Kip1 protein localization, in acute myelogenous leukemia cells.
The frequency of Akt/PKB phosphorylation was significantly higher in the high C:N ratio group compared with the low C:N ratio group (P  0.042).
Table 2 Cell cycle distribution according to the C:Na ratio of p27Kip1 localization
C:N ratio of p27Kip1 localization
PLow (n  44) High (n  44)
G0/G1 79.4  27.0% 86.4  11.9% NS
G2/M 15.9  27.1% 6.6  2.5% NS
S 7.8  12.3% 14.0  27.7% NS
a C:N, cytoplasmic to nuclear; NS, not significant.
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univariate and multivariate analysis. A multivariate analysis was used to test
for the independent prognostic significance of the variables using the Cox
proportional hazards regression model. Patients alive and still in remission at
their last follow-up examination were censored in the analysis. A P 0.05 was
used to indicate statistical significance. All of the calculations were performed
using the SPSS software, version 11.0.1 (SPSS Inc., Chicago, IL).
RESULTS
The p27Kip1 Protein Expression in AML Cells. Western blot
analysis demonstrated that the p27Kip1 protein was expressed to a
variable degree in 88 (88.9%) of 99 AML cases (Fig. 1A). To perform
the quantitative analysis, the expression level of p27Kip1 protein was
evaluated in the AML cells (L) by normalization as follows:
Lc  p27Kip1 (L)/-tubulin (L) as determined by Western blot
analysis. In this study, the Lc ranged from 0 to 68.3 (median, 8.08).
There was no association between the cellular levels of the p27Kip1
protein and the various clinical parameters such as age, French-
American-British classification, WBC count, lactic dehydrogenase
level, cell-cycle distribution, cytogenetics, complete remission rate,
DFS, and OS (data not shown).
Subcellular Localization of p27Kip1 Protein in AML Cells.
Next, the subcellular localization of the p27Kip1 protein was exam-
ined in the leukemia cells obtained from 88 AML patients. Western
blot analysis of the fractionated cell lysates demonstrated that the
subcellular localization of the p27Kip1 protein was different, accord-
ing to the patients (Fig. 1B). To perform the quantitative analysis, the
relative levels of the p27Kip1 expression at the subcellular compart-
ment were represented as the C:N ratio of the p27Kip1 protein levels
as shown in the following data: C:N  p27Kip1(C)/p27Kip1(N) as
determined by the Western blot analysis. In this study, the C:N ratios
ranged from 0 to 127.21 (median, 1.97). For the practical evaluations,
the median value was used as a cutoff value for the levels of subcel-
lular localization of the p27Kip1 in the AML cells. Using this value,
the AML cases were classified into two groups; the high and low C:N
ratio groups (n  44 for both; Table 1). Next, the association between
the C:N ratio of the p27Kip1 localization and various clinical param-
eters in AML were analyzed. As shown in Table 1, the C:N ratio of
the p27Kip1 localization was not correlated with age, gender, WBC
count, lactic dehydrogenase level, French-American-British classifi-
cation, or cytogenetics. Cell cycle analysis demonstrated that the
fraction of cells in the G0/G1 phase were not different between the
AML cells, showing either a high or low C:N ratio of the p27Kip1
localization (86.4  11.9 and 79.4  27.0%, respectively; Table 2).
Likewise, the C:N ratio of the p27Kip1 localization was not correlated
with the fractions of the cells in the G2-M or S-phase (Table 2).
Correlation between Constitutive Akt/PKB Phosphorylation
and p27Kip1 Localization. The constitutive phosphorylation of
Ser473 Akt/PKB was demonstrated in 58 (58.6%) of 99 cases (Fig.
2A). Cell cycle analysis showed that neither the fraction of cells in the
G0/G1 phase, G2-M phase, or S phase were different, according to the
Fig. 3. Confocal microscopic analysis of the p27Kip1 protein localization in acute myelogenous leukemia (AML) cells in relation to the constitutive Akt or protein kinase B
(Akt/PKB) phosphorylation. A, A representative pAkt/PKB-positive AML specimen was stained for p27Kip1 by FITC (green) as described in “Materials and Methods.” The confocal
image demonstrated the preferential localization of the p27Kip1 protein to the cytoplasm. Nuclear counterstain was carried out with 4,6-diamidino-2-phenylindole (DAPI) staining
(blue). Cyan represents the merged images. B, nuclear staining of the p27Kip1 protein was evident in the representative AML case, where no Akt/PKB phosphorylation was seen.
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phosphorylation of Akt/PKB (data not shown). Next, the association
of the phosphorylation of Akt/PKB and localization of the p27Kip1
protein was examined in the AML cells. Akt/PKB phosphorylation
was observed more frequently in the high C:N ratio group compared
with the low C:N ratio group (77.3% versus 54.5%, P  0.042; Fig.
2B). The mean value of the C:N ratio of the p27Kip1 localization was
significantly higher in the pAkt/PKB-positive AML cases compared
with the pAkt/PKB-negative AML cases (18.15  4.2 versus
9.2  3.3, P  0.043; Fig. 2A). The confocal microscopic analysis
revealed the p27Kip1 protein to be preferentially localized to the
cytoplasm in a pAkt/PKB-positive AML case (Fig. 3A). In contrast,
the nuclear staining of the p27Kip1 protein was evident in a pAkt/
PKB-negative AML case (Fig. 3B).
The p27Kip1 Mislocalization Induced by Akt/PKB Overexpres-
sion in Leukemia Cells. To investigate whether the active Akt/
PKB directly affects the localization of the p27Kip1 protein in
leukemia cells, the U937 leukemia cells were transfected using the
pcDNA3-myristoylated-Akt/PKB or pcDNA3-DN-Akt/PKB ex-
pression vectors (Fig. 4A). As shown in Fig. 4B, the expression of
the p27Kip1 protein was preferentially localized to the cytoplasm
of the myristoylated-Akt/PKB-transfected U937 cells. In contrast,
the DN-Akt/PKB-transfected U937 cells revealed a reduced level
of the p27Kip1 in the cytoplasm, but increased the p27Kip1 levels
in the nuclei.
The p27Kip1 Localization as a Prognostic Variable in AML.
The complete remission rate of the patients with the high C:N ratio of
the p27Kip1 localization was lower than that with the low C:N ratio
(75% versus 95%), but without statistical significance (P  0.116;
Table 1). A survival analysis using the Kaplan-Meier method dem-
onstrated that the high C:N ratio group had a significantly shorter DFS
than the low C:N ratio group (Fig. 5A; P  0.0353 by log-rank test).
The OS rate was also significantly lower in the high C:N ratio group
compared with the low C:N ratio group (Fig. 5B; P  0.0023). The
DFS estimates at 5 years for patients with a high or low C:N ratio of
p27Kip1 localization were 19.0 (SE  14.6%) and 58.2%
(SE 12.4%), respectively (P 0.0353). The OS estimates at 5 years
for patients with a high or low C:N ratio were 10.8 (SE  8.4%) and
52.6% (SE  11.2%), respectively (P  0.0023). The univariate
analysis revealed that the C:N ratio of the p27Kip1 localization was a
strong prognostic factor both of the DFS and OS (Table 3). A
multivariate analysis of the covariates in the Cox regression model
demonstrated that the C:N ratio of the p27Kip1 protein localization
remained as an independent prognostic factor of the DFS [relative risk
(95% confidence interval) 2.326 (0.989–5.466), P 0.043] and the
OS [relative risk (95% confidence interval)  2.399 (1.255–4.585),
P  0.008] (Table 4).
Fig. 4. Effects of myristoylated Akt or protein kinase B (Myr-Akt/PKB) and DN-Akt/
PKB transfection on the subcellular localization of the p27kip protein in the U937 cells.
The U937 cells were transiently transfected with Myr-Akt/PKB or DN-Akt/PKB con-
structs as described in “Materials and Methods.” A, the total cell lysates were analyzed by
Western blotting, using antibodies against total Akt/PKB and Ser473 pAkt/PKB. B,
Myr-Akt/PKB-transfected and DN-Akt/PKB-transfected U937 cells were subjected to the
subcellular fractionation. Equal amounts of proteins (20 g) from the nuclear and
cytoplasmic fractions were separated by SDS-PAGE and then probed with the anti-
p27kip1 antibody. The -tubulin was used as a loading control.
Fig. 5. Kaplan-Meier survival curves for the disease-free survival and overall survival rates of patients with acute myelogenous leukemia, according to the cytoplasmic to nuclear
ratio (C:N) ratio of the p27Kip1 localization. The acute myelogenous leukemia cases with the high C:N ratio of the p27Kip1 localization had significantly lower disease-free survival
(A) and overall survival rates (B) compared with the cases with the low C:N ratio (P  0.0353 and P  0.0023, respectively). The log-rank statistic was used to test for the difference
in survival times between the groups.
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DISCUSSION
In this study, the cytoplasmic mislocalization of the p27Kip1 pro-
tein was demonstrated in a substantial proportion of the AML cases.
The p27Kip1 mislocalization to the cytoplasm was highly correlated
with the constitutive phosphorylation of Akt/PKB in the leukemic
cells and with a poor prognosis in AML. However, the mere cellular
levels of the p27Kip1 protein were not correlated with the clinical
outcome. This study supports a growing body of evidences suggesting
that the cytoplasmic p27Kip1 may play a role as an oncoprotein with
antiapoptotic properties (26–28, 46).
Much less is known about the localization of p27Kip1 protein
during the cell cycle progression. To inhibit cyclin E/CDK2, p27Kip1
needs to be imported into the nucleus (3). As cells progress along the
cell cycle, the p27Kip1 protein shuttles between the nucleus and
cytoplasm (47). The cytoplasmic redistribution of p27Kip1 induced
by mitogenic stimulation is dependent on the phosphorylation of the
Ser10 residue (47). Recently, it was demonstrated that p27Kip1 phos-
phorylation induced by the oncogenically activated kinase Akt/PKB
disables the nuclear localization capacity of p27Kip1 (33, 34, 41).
Akt/PKB can directly phosphorylate p27Kip1 at a Thr157 residue
within the nuclear localization signal both in vitro and in vivo (33, 41).
This Akt/PKB-dependent phosphorylation results in an impairing of
its nuclear import, leading to cytoplasmic retention of the p27Kip1,
abrogation of its CDK2 inhibitory activity, and cell cycle progression
(41). The Akt/PKB phosphorylation in primary human breast cancer
statistically correlated with the cytoplasmic localization of the
p27Kip1 protein (41). An inhibition of the Akt/PKB activation with
the phosphatidylinositol 3-kinase inhibitor LY294002 or by the over-
expression of DN Akt/PKB allele allows return of the p27Kip1 to the
nucleus, resulting in an inhibition of CDK2 activity (33, 34, 41). As
with Ser10, Thr157-phosphorylated p27Kip1 is detected almost exclu-
sively in the cytoplasmic compartment (34, 41). Whereas Ser10 phos-
phorylation promotes the nuclear export of the p27Kip1, Thr157 phos-
phorylation seems to impair its import into the nuclei (33). The
complex relationship between the p27Kip1 localization and degrada-
tion still remains to be addressed. Previous experimental evidence
suggests that at least in breast cancer cells, the proteolysis and
mislocalization of p27Kip1 occur through separate pathways (33).
Although the p27Kip1 phosphorylation at the Ser10 or Thr157 residue
was not evaluated in this study, the close correlation between the
cytoplasmic mislocalization of p27Kip1 and the constitutive Akt/PKB
phosphorylation suggests that an Akt/PKB-mediated Thr157 phospho-
rylation mechanism is present in a substantial proportion of AML
cases. In this study, the induced Akt/PKB activation resulted in a
remarkable increase in the levels of cytoplasmic p27Kip1 in the U937
leukemia cells. Transfection of the U937 cells with a DN Akt/PKB
construct resulted in a recovery of the nuclear localization of the
p27Kip1 protein. These findings strongly suggest that Akt/PKB acti-
vation is one of the crucial mechanisms determining the localization
of the p27Kip1 protein in leukemia cells. However, because the
Akt/PKB phosphorylation was not observed in a certain proportion of
AML cases showing the cytoplasmic mislocalization of p27Kip1 in
this study, the contribution of other intracellular oncogenic pathways
to the cytoplasmic mislocalization and dysregulation of p27Kip1
protein cannot be excluded.
Whatever the mechanism is, it is important to understand the
biological significance of the cytoplasmic mislocalization of p27Kip1
in AML cells. The export of p27Kip1 from the nucleus to the cyto-
plasm serves to remove the inhibitory activity of p27Kip1 against
cyclin E/CDK2 (34, 41). This allows an activation of an increasing
number of cyclin E/CDK2 complexes, which are then free to phos-
phorylate the p27Kip1. The transfection studies suggested that the
relocalization of the p27Kip1 from the nucleus to the cytoplasm was
sufficient to sustain the cellular proliferation (34, 41, 48). Another
issue that needs to be addressed is whether the cytoplasmic mislocal-
ization of the p27Kip1 observed in cancers merely contributes to
abrogate its function or induces the p27Kip1 to acquire new cytoplas-
mic functions. The p27Kip1 was demonstrated to inhibit the drug-
induced apoptosis (49), although it is uncertain whether the nuclear
and cytoplasmic p27Kip1 differ in their efficiencies to protect the
cells from apoptosis.
Only recently, the cytoplasmic mislocalization of p27Kip1 in tumor
cells has been identified as a mechanism whereby cancer cells pro-
mote carcinogenesis in humans (28). Displacement of p27Kip1 into
the cytoplasm contributes to the anchorage-independent growth of
human transformed fibroblasts by maintaining high cyclin/CDK ac-
tivity in the nucleus (31). Cytoplasmic mislocalization of p27Kip1 has
been reported for a number of human malignancies (26–28, 33, 34,
41). It appears that the preferential location of p27Kip1 in the cyto-
plasm of tumor cells is predictive of a more aggressive clinical
behavior (33). It was shown that the patients with Barrett’s adenocar-
cinoma or breast carcinoma, which presented the cytoplasmic
p27Kip1, showed decreased overall survivals compared with the
Table 3 Univariate analysis of age, WBC,a cytogenetics, and the C:N ratio of p27Kip1




60 vs. 60 0.3300 0.7068 0.1100
WBC (109/l)
30 vs. 30 0.0200 0.5353 0.9890
Cytogenetics
Non-unfavorablec vs. unfavorable 1.000 0.8231 0.8659
p27Kip1 localization (C:N ratio)
Low vs. high 0.116 0.0353 0.0023
a WBC, white blood cell; C:N, cytoplasmic to nuclear; CR, complete remission; DFS,
disease-free survival; OS, overall survival; AML, acute myelogenous leukemia.
b Log-rank test.
c Favorable plus intermediate prognostic group.
Table 4 Multivariate analysis of DFSa and OS in AML patients
DFS OS
P RR (95% CI) P RR (95% CI)
Age (yr)
60 vs. 60 0.974 0.982 (0.320–3.007) 0.010 1.374 (0.686–2.753)
WBC (109/l)
30 vs. 30 0.790 0.790 (0.334–1.866) 0.786 1.003 (0.548–1.836)
Cytogenetics
Non-unfavorable vs. favorable 0.940 1.032 (0.448–2.378) 0.920 1.046 (0.565–1.937)
p27Kip1 localization (C:N ratio)
Low vs. high 0.043 2.326 (0.989–5.466) 0.008 2.399 (1.255–4.585)
a DFS, disease-free survival; OS, overall survival; AML, acute myelogenous leukemia; RR, relative risk; CI, confidence interval; WBC, white blood cell; C:N, cytoplasmic to
nuclear.
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patients who present with nuclear p27Kip1 (28, 41). In this study, the
WBC count or cytogenetics, which had been generally considered as
a prognostic factor in adult AML, was not significantly associated
with prognosis. These findings were in agreement with the previous
report, which revealed that neither WBC nor cytogenetics was an
independent prognostic factor in adult AML (50). Instead, we dem-
onstrate for the first time that the p27Kip1 mislocalization is the
strong prognostic factor in AML cases, whereas the total cellular
levels of p27Kip1 do not have any prognostic value. The patients with
high C:N ratio of the p27Kip1 localization showed a significantly
shorter DFS and OS compared with the patients with low C:N ratio of
p27Kip1 localization. The multivariate analysis revealed that the C:N
ratio of the p27Kip1 localization remained an independent prognostic
factor both the DFS and OS.
In conclusion, the cytoplasmic mislocalization of the p27Kip1 protein
was observed in a substantial proportion of the AML cases. The mislo-
calization, not the cellular levels, of the p27Kip1 protein was highly
associated with the constitutive phosphorylation of Akt/PKB and a poor
prognosis in AML. Although the biological functions of cytoplasmic
p27Kip1 protein and the genetic alterations that cause its mislocalization
to the cytoplasm should be evaluated additionally, these findings suggest
that the cytoplasmic mislocalization of p27Kip1 is an independent prog-
nostic factor in AML, and the Akt/PKB-p27Kip1 pathway may be a
ready target for antileukemia therapy.
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